Literature DB >> 25599162

A retrospective comparison of BU-fludarabine and BU-CY regimens in elderly patients or in patients with comorbidities who received unmanipulated haploidentical hematopoietic SCT.

Y-Q Sun1, L-P Xu1, X-H Zhang1, D-H Liu1, H Chen1, Y Wang1, C-H Yan1, J-Z Wang1, F-R Wang1, Y-Y Zhang1, K-Y Liu1, X-J Huang2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25599162     DOI： 10.1038/bmt.2014.303

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  14 in total

1.  Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.

Authors:  George B McDonald; John T Slattery; Michelle E Bouvier; Song Ren; Ami L Batchelder; Thomas F Kalhorn; H Gary Schoch; Claudio Anasetti; Ted Gooley
Journal:  Blood       Date:  2002-10-24       Impact factor: 22.113

2.  Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Authors:  Mohamed L Sorror; Michael B Maris; Rainer Storb; Frederic Baron; Brenda M Sandmaier; David G Maloney; Barry Storer
Journal:  Blood       Date:  2005-06-30       Impact factor: 22.113

3.  [The efficacy and safety of modified busulfan/fludarabine conditioning regimen in elderly or drug-intolerable patients with hematologic malignancies].

Authors:  Feng-rong Wang; Xiao-jun Huang; Dai-hong Liu; Huan Chen; Yu Wang; Fei-fei Tang; Yu-qian Sun; Hai-xia Fu; Kai-yan Liu; Lan-ping Xu
Journal:  Zhonghua Nei Ke Za Zhi       Date:  2013-12

4.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

5.  [Reduced intensity of BuCy conditioning regimen for transplantation in the treatment of malignant hematologic diseases].

Authors:  Huan Chen; Dao-pei Lu; Xiao-jun Huang; Kai-yan Liu; Lan-ping Xu; Wei Han; Han-yun Ren; Yu-hong Chen; Dai-hong Liu; Jin Lu; Qian Jiang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2005-05

6.  EBMT risk score can predict the outcome of leukaemia after unmanipulated haploidentical blood and marrow transplantation.

Authors:  H-T Wang; Y-J Chang; L-P Xu; D-H Liu; Y Wang; K-Y Liu; X-J Huang
Journal:  Bone Marrow Transplant       Date:  2014-04-28       Impact factor: 5.483

7.  Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS.

Authors:  Borje S Andersson; Marcos de Lima; Peter F Thall; Xuemei Wang; Daniel Couriel; Martin Korbling; Soonja Roberson; Sergio Giralt; Betty Pierre; James A Russell; Elizabeth J Shpall; Roy B Jones; Richard E Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2008-06       Impact factor: 5.742

8.  Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine.

Authors:  Je-Hwan Lee; Young-Don Joo; Hawk Kim; Hun Mo Ryoo; Min Kyoung Kim; Gyeong-Won Lee; Jung-Hee Lee; Won-Sik Lee; Jae-Hoo Park; Sung-Hwa Bae; Myung Soo Hyun; Dae-Young Kim; Sung-Doo Kim; Young Joo Min; Kyoo-Hyung Lee
Journal:  J Clin Oncol       Date:  2012-11-05       Impact factor: 44.544

9.  Substitution of cyclophosphamide in the modified BuCy regimen with fludarabine is associated with increased incidence of severe pneumonia: a prospective, randomized study.

Authors:  Dai-hong Liu; Lan-ping Xu; Xiao-hui Zhang; Yu Wang; Chen-hua Yan; Jing-zhi Wang; Feng-rong Wang; Yu-qian Sun; Yu Ji; Yuan-yuan Zhang; Kai-yan Liu; Xiao-jun Huang
Journal:  Int J Hematol       Date:  2013-11-17       Impact factor: 2.490

10.  Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic stem cell transplantation: a prospective and multicenter study.

Authors:  Hui Liu; Xiao Zhai; Zhaoyang Song; Jing Sun; Yang Xiao; Danian Nie; Yu Zhang; Fen Huang; Hongsheng Zhou; Zhiping Fan; Sanfang Tu; Yonghua Li; Xutao Guo; Guopan Yu; Qifa Liu
Journal:  J Hematol Oncol       Date:  2013-02-08       Impact factor: 17.388
View more
  6 in total

Review 1.  The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China-recommendations from the Chinese Society of Hematology.

Authors:  Lanping Xu; Hu Chen; Jing Chen; Mingzhe Han; He Huang; Yongrong Lai; Daihong Liu; Qifa Liu; Ting Liu; Ming Jiang; Hanyun Ren; Yongping Song; Zimin Sun; Jianmin Wang; Depei Wu; Daobin Zhou; Ping Zou; Kaiyan Liu; Xiaojun Huang
Journal:  J Hematol Oncol       Date:  2018-03-02       Impact factor: 17.388

2.  Pilot study using post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate GVHD prophylaxis for older patients receiving 10/10 HLA-matched unrelated donor hematopoietic stem cell transplantation.

Authors:  Mithun Vinod Shah; Rima M Saliba; Gabriela Rondon; Julianne Chen; Doris Soebbing; Ioana Rus; Amin Alousi; Betul Oran; Partow Kebriaei; Muzaffar Qazilbash; Simrit Parmar; Chitra Hosing; Issa F Khouri; Uday R Popat; Richard E Champlin; Stefan O Ciurea
Journal:  Bone Marrow Transplant       Date:  2018-10-18       Impact factor: 5.483

3.  Haploidentical Stem Cell Transplantation With a Novel Conditioning Regimen in Older Patients: A Prospective Single-Arm Phase 2 Study.

Authors:  Yu-Qian Sun; Ting-Ting Han; Yu Wang; Chen-Hua Yan; Feng-Rong Wang; Zhi-Dong Wang; Jun Kong; Yu-Hong Chen; Huan Chen; Wei Han; Yao Chen; Yuan-Yuan Zhang; Xiao-Hui Zhang; Lan-Ping Xu; Kai-Yan Liu; Xiao-Jun Huang
Journal:  Front Oncol       Date:  2021-02-26       Impact factor: 6.244

Review 4.  Update of the "Beijing Protocol" haplo-identical hematopoietic stem cell transplantation.

Authors:  Meng Lv; Ying-Jun Chang; Xiao-Jun Huang
Journal:  Bone Marrow Transplant       Date:  2019-08       Impact factor: 5.483

Review 5.  How do we choose the best donor for T-cell-replete, HLA-haploidentical transplantation?

Authors:  Ying-Jun Chang; Leo Luznik; Ephraim J Fuchs; Xiao-Jun Huang
Journal:  J Hematol Oncol       Date:  2016-04-12       Impact factor: 17.388

6.  [Outcomes of allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome without excess blasts].

Authors:  Y Yu; X H Zhang; Y Wang; H Chen; W Han; Y Chen; Y Y Zhang; Y Y Chen; X D Mo; H X Fu; C H Yan; Y Q Sun; F R Wang; J Z Wang; K Y Liu; X J Huang; L P Xu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-10-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.